What is the recommended treatment for mast cell activation syndrome?

Treatment of Mast Cell Activation Syndrome

Begin with high-dose non-sedating H1 antihistamines at 2–4 times the standard FDA-approved dose combined with an H2 antihistamine as first-line therapy for all patients with MCAS. 1, 2

First-Line Pharmacologic Therapy

• Initiate non-sedating H1 antihistamines (cetirizine, fexofenadine, or loratadine) at 2–4 times the standard FDA dose—for example, cetirizine 20–40 mg daily or fexofenadine 360–720 mg daily—to control dermatologic manifestations (urticaria, flushing, pruritus), tachycardia, and abdominal discomfort. 1, 2

• Add an H2 antihistamine (famotidine 20–40 mg twice daily) concurrently to address gastrointestinal symptoms (cramping, diarrhea, nausea) and attenuate cardiovascular manifestations. 1, 2

• Assess clinical response after 2–6 weeks at these doses before declaring treatment failure; approximately one-third of patients achieve complete symptom resolution with this regimen alone. 1

• Common pitfall: Using standard antihistamine doses instead of the guideline-recommended 2–4× doses is the most frequent cause of apparent treatment resistance. 1

Second-Line Add-On Therapies (Stepwise Escalation)

When first-line therapy provides insufficient control after an adequate trial:

Mast Cell Stabilizers

• Oral cromolyn sodium 200 mg four times daily is particularly effective for persistent gastrointestinal symptoms (abdominal distension, diarrhea, colic) and may improve neuropsychiatric manifestations. 1, 2

• Titrate slowly over 1–2 weeks starting at a low dose to minimize side effects (headache, sleepiness, irritability, abdominal pain, diarrhea). 1

• Maintain full dose for at least 1 month before judging efficacy, as therapeutic effect emerges gradually. 1, 2

• Cromolyn can also reduce cutaneous symptoms (pruritus, flushing) despite low systemic absorption. 1

Leukotriene Antagonists

• Add montelukast 10 mg daily (or zafirlukast or zileuton) when urinary leukotriene E4 is elevated or antihistamine response is suboptimal. 1, 2

• Leukotriene antagonists work synergistically with H1 antihistamines and are especially effective for dermatologic symptoms, bronchospasm, and gastrointestinal manifestations. 1, 2

Ketotifen (Compounded)

• Ketotifen 0.5 mg twice daily (titrated to 4–8 mg daily over several weeks) provides dual action as both a mast cell stabilizer and H1 antihistamine. 1

• Particularly effective for dermatologic manifestations (rash, flushing, pruritus) and works synergistically with montelukast. 1

• Must be obtained through a compounding pharmacy as it is not FDA-approved in oral form in the United States. 1

• Caution: Ketotifen causes sedation and cognitive decline risks, especially in elderly patients. 2

Cyproheptadine

• Cyproheptadine is specifically recommended for patients with prominent nausea and diarrhea and may have migraine preventive properties. 3, 2

Aspirin (for Specific Mediator Elevation)

• Aspirin 325–650 mg twice daily may reduce flushing and hypotensive episodes in patients with documented elevation of urinary 11β-prostaglandin F2α. 1, 2

• Must be introduced in a controlled clinical setting with emergency equipment available, as aspirin can trigger mast cell degranulation in susceptible individuals. 1, 2

• Contraindicated in patients with known NSAID hypersensitivity. 1

Third-Line Therapies for Refractory Disease

Approximately one-third of patients require combination regimens beyond first- and second-line agents. 1

Systemic Corticosteroids

• Prednisone 0.5 mg/kg/day (approximately 50 mg for a typical adult) with a slow taper over 1–3 months for severe refractory symptoms. 1, 2

• Taper rapidly once control is achieved to limit adverse effects; long-term use should be avoided. 3, 1

• For acute severe episodes requiring hospitalization (marked dehydration, dysphagia, significant weight loss), systemic corticosteroids may be administered emergently. 1

Omalizumab (Anti-IgE Biologic)

• Omalizumab should be considered when MCAS remains symptomatic despite optimal mediator-targeted therapy, particularly for preventing recurrent anaphylaxis. 3, 1, 4

• Dosing: Most commonly 150 mg every 2 weeks, though higher doses (≥300 mg/month) are associated with better complete response rates. 4

• Efficacy: In systematic review of 28 patients with refractory MCAS, 61% achieved partial response and 18% achieved complete response; omalizumab successfully ameliorated anaphylaxis and allowed discontinuation of systemic glucocorticoids in two of three patients. 4

• Response pattern is not influenced by sex or mast cell clonality. 4

• Low-dose omalizumab (150 mg monthly) has demonstrated sustained 5-year clinical response in idiopathic MCAS and should be considered for maintenance management for its cost and quality-of-life benefits. 5

Advanced Therapies for Clonal MCAS

• Midostaurin (multikinase inhibitor) for advanced systemic mastocytosis with refractory symptoms; prophylactic ondansetron 30–60 minutes before dosing mitigates nausea. 1

• Cytoreductive therapies (interferon-α, cladribine) for life-threatening manifestations unresponsive to antimediator drugs. 1, 2

• Avapritinib (recently FDA-approved for indolent systemic mastocytosis) and other tyrosine kinase inhibitors targeting KIT can efficiently induce mast cell depletion. 6

• Lirentelimab (anti-Siglec-8 antibody) showed promising results in indolent systemic mastocytosis. 6

Emergency Management and Safety

Epinephrine Auto-Injectors

• Prescribe two epinephrine auto-injectors (0.3 mg for adults) for all MCAS patients with a history of systemic anaphylaxis or severe reactions, as 20–50% of systemic mastocytosis patients experience systemic anaphylaxis. 3, 1, 2

• Train patients to use epinephrine when anaphylaxis criteria are met (acute onset involving skin/mucosa plus respiratory compromise or hypotension). 7

Acute Episode Management

• Patients should assume a supine position promptly during hypotensive episodes to prevent cardiovascular collapse. 3, 1, 2

• Albuterol (nebulizer or metered-dose inhaler) for bronchospasm symptoms. 2

• For prolonged episodes, corticosteroids may be required. 8

Perioperative and Procedural Management

• Premedication with H1/H2 antihistamines plus corticosteroids is recommended before surgery, invasive procedures, or contrast imaging to prevent anaphylaxis. 1, 2

• For procedures with prior mast cell activation: Prednisone 50 mg at 13 hours, 7 hours, and 1 hour before the intervention. 1

• Preferred anesthetic agents: Propofol, sevoflurane, isoflurane for induction/maintenance; fentanyl or remifentanil for analgesia (avoid morphine or codeine). 1, 2

• Safer local anesthetics: Lidocaine and bupivacaine. 2

• Avoid: Atracurium and mivacurium due to risk of mast cell activation. 2

• Analgesic stewardship: Untreated pain is a potent mast cell trigger; therefore, analgesics should not be withheld. 1

• Multidisciplinary coordination among surgical, anesthesia, and allergy teams is essential, including review of prior anesthetic records and avoidance of known triggers. 1

Trigger Avoidance

• Insect venoms (hymenoptera stings) are well-documented precipitants. 1

• Temperature extremes (heat or cold) should be avoided. 1

• Alcohol consumption can trigger episodes and should be limited or avoided. 1

• Certain medications known to provoke mast cell degranulation must be identified and excluded. 1

• Introduce new medications cautiously as some patients may experience paradoxical reactions; conduct trials in a controlled setting with emergency equipment available. 2

Dietary Considerations

• Pharmacologic management takes priority over dietary restriction; the American Academy of Allergy, Asthma, and Immunology emphasizes that MCAS management centers on blocking mediator receptors, inhibiting mediator synthesis, and preventing mediator release, rather than dietary restriction. 1

• Food elimination alone without pharmacologic management is insufficient and not guideline-recommended. 1

• If dietary interventions are pursued, they should be provided together with qualified nutritional counseling to prevent the hazards of overly restrictive eating patterns. 1

• Histamine can be produced by bacteria that colonize mucosal surfaces or contaminate ingested foods, which may theoretically trigger symptoms in susceptible individuals, but universal dietary restrictions are not specified in guidelines. 1

Monitoring and Follow-Up

• Routine history, physical examination, and laboratory testing every 6–12 months for patients with stable MCAS, or sooner if new clinical issues arise. 1

• Symptom burden and quality of life should be evaluated with validated tools: Mast Cell Activation Symptom (MSAF) questionnaire and Mast Cell Quality of Life (MQLQ) questionnaire. 1

• DEXA scan every 1–3 years for individuals with osteopenia or osteoporosis. 1

Referral Indications

• Refer to a specialized mast cell disorder center for refractory disease, to facilitate enrollment in research studies, and to ensure access to advanced diagnostic assays (urinary mediators, sensitive KIT testing, tryptase genotyping). 1, 2

Prognosis

• Approximately two-thirds of patients achieve complete or major symptom control with appropriate mediator-targeted therapy. 1

• A Mayo Clinic cohort followed >15 years showed no progression to systemic mastocytosis among clonal MCAS patients. 1

• Data from indolent systemic mastocytosis indicate normal life expectancy, suggesting a generally favorable prognosis when disease remains indolent. 1

Critical Diagnostic Pitfalls Leading to Treatment Failure

Before labeling a patient as treatment-resistant, verify:

• All three mandatory diagnostic criteria are met: (1) episodic symptoms involving ≥2 organ systems simultaneously, (2) documented mediator elevation on ≥2 separate occasions, and (3) clinical response to mast cell-targeted therapy. 1, 7

• Adequate dosing and duration: Antihistamines at 2–4× standard doses for ≥2–6 weeks; cromolyn sodium at full dose for ≥1 month. 1

• Secondary causes excluded: IgE-mediated allergy, cofactor-dependent food allergy, NSAID hypersensitivity, drug reactions, infections. 1, 7

• Not a genetic mimic: Hereditary alpha-tryptasemia (TPSAB1 duplications) produces chronically elevated tryptase and overlapping symptoms but represents a distinct genetic disorder. 1

• Overdiagnosis avoided: MCAS is substantially overdiagnosed when based solely on nonspecific symptoms, single organ system involvement, chronic (rather than episodic) symptoms, or symptoms without documented mediator elevation. 1